Intest Res Search

CLOSE


Published online September 1, 2017.
Long-term safety and efficacy of adalimumab for intestinal Behçet's disease
This issue chosen by the Editor of Intestinal Research is the open label study following a phase 3 clinical trial about long-term safety and efficacy of adalimumab for intestinal Behçet's disease (BD) performed by Inoue et al.

Previously, 52 week results of a phase 3 clinical study demonstrating the efficacy and safety of adalimumab in intestinal BD was reported in the same group. Based on this open-label clinical trial, adalimumab was recently approved and recommended as a standard therapy for intestinal BD in Japan, Taiwan and South Korea.

In this study, Inoue et al. evaluated safety profile and effectiveness of adalimumab for the treatment of intestinal BD through 100 weeks.

Read more about safety and effectiveness of adalimumab in intestinal Behçet's disease.

In addition to this article, read other review articles about BD.

Best regards,
Related article
  • SCImago Journal & Country Rank
  • AOCC 2018
  • CSIBD
  • JSIBD
  • kasid
  • TSIBD
  • CCF
  • PubMed Central
  • PubMed
  • KoreaMed
  • KoMCI
  • Scopus
  • Directory of Open Access Journals (DOAJ)
  • Science Central
  • GoogleScholar
  • EBSCO
  • Similarity Check
  • Crossref Cited-by Linking
  • CrossMark
  • Funder Registry
  • ORCID
  • COPE
  • KOFST
  • TrendMD


ABOUT
ARTICLE CATEGORY

Browse all articles >

BROWSE ARTICLES
EDITORIAL POLICY
AUTHOR INFORMATION
Editorial Office
Room 305, Lotte Gold Rose II, 31 Seolleung-ro 86-gil, Gangnam-gu, Seoul 06193, Korea
Tel: +82-2-957-6145    Fax: +82-2-957-6146    E-mail: thekasid@irjournal.org                

Copyright © 2019 by Korean Association for the Study of Intestinal Diseases. All rights reserved.

Developed in M2community

Close layer
prev next